MARK2 and chronic myelogenous leukemia, BCR-ABL1 positive: The expression of antiapoptotic genes such as survivin, B-cell lymphoma extra-large (BCL-xl) and B-cell lymphoma w (BCL-w) and activation of serine/threonine kinase/extracellular regulated kinase (Akt/ERK) and NFκB pathways is significantly increased in CML cells treated with CML-derived sEVs (70).